COLORECTAL CANCER WITH LIVER METASTASIS AND TREATMENT WITH ANTI-ANGIOGENIC DRUGS: RESPONSE EVALUATION WITH DIFFUSION-WEIGHTED MRI
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Colorectal cancer is the third most common malignancy and the third leading cause of cancer-related death worldwide. Recently, the introduction of novel drugs (anti- angiogenic drugs) has led to a significant improvement in the survival rates of patients with metastatic colorectal cancer. The RECIST (Response Evaluation Criteria for Solid Tu- mors) parameters cannot adequately detect important effects of treatment and response to the application of these new drugs. New radiologic methods, such as diffusion- weighted MRI, could help to assess the quality and quantity of the response more accu- rately. Diffusion-weighted MRI imaging is based on a technique sensitive to the Brownian motion of water molecules over short distances.
This article describes our experience with this method in patients with liver metastasis from colorectal cancer after treatment with bevacizumab.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.